Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6741-6747

  Li, Ying Yi ^a   Popivanova, Boryana K ^a   Nagai, Yuichiro ^b   Ishikura, Hiroshi ^b   Fujii, Chifumi ^a   Mukaida, Naofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLSERINE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PIM 3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

EID: 33746122005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4272     Document Type: Article

References (30)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
2. Feldman JD, Vician L, Crispino M, et al. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998;273:16535-43.
3. Konietzko U, Kauselmann G, Scafidi J, et al. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBOJ 1999;18:3359-69.
4. Giza CC, Prins ML, Hovda DA, Herschman HR, Feldman JD. Genes preferentially induced by depolarization after concussive brain injury: effects of age and injury severity. J Neurotrauma 2002;19:387-402.
5. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol 2003;23:3897-908.
6. Fujii C, Nakamoto Y, Lu P, et al. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005;114:209-18.
7. van Lohize M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphogenesis in pim-I transgenic mice: cooperation with c-myc and N-myc in murine leukemia-virus-induced tumors. Cell 1989;56:673-82.
8. Moroy T, Verbeek S, Ma A, Achacoso P, Berns A, Alt F. Eμ N- and Eμ L-myc cooperate with Eμ pim-1 to generate lymphoid tumors at high frequency in double transgenic mice. Oncogene 1991;6:1941-8.
9. Allen JD, Verhoeven E, Domen J, van der Volk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997;15:1133-41.
10. Chen WW, Chan DC, Donald C, Lilly MB, Kraft A. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51.
11. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
12. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic functions. Mol Cell 2005;17:393-403.
13. L. Mol Cell Biol 1997;17:7040-6.
14. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996;87:619-28.
15. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
16. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates Bad on serine 112 and reverses Bad-induced cell death. J Biol Chem 2003;278:45358-67.
17. 112 gatekeeper site. FEBS Lett 2004;571:43-9.
18. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, BradyJN. Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005;24:6719-28.
19. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975;15:741-7.
20. Yunis AA, Arimura GK, Russin D. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977;19:218-35.
21. Yano T, Ishikura H, Kato H, et al. Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients. Jpn J Cancer Res 2001;92:83-7.
22. Kloppel G, Hruban RH, Longnecker DS. Tumours of the exocrine pancrease. Stanley SR, Aaltonen LA, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system Lyon: IARC Publication; 2001. 219-51.
23. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the Pim-1 proto-oncogene-encoded protein kinase. Biochem Cell Biol 1997;75:153-62.
24. Bullock AN, Debreczeni J, Amos A, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82. Epub 2005 Oct 13
25. L by the MAPK/Erk Kinase. J Biol Chem 1999;274:31108-13.
26. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1997;13:2905-27.
27. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo JL, Rosen N. The Bad protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97.
28. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185-95.
29. Amaravadi R, Thompson CB. The survival kinase Akt and Pirn as potential pharmacological targets. J Clin Invest 2005;115:2618-24.
30. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all Pim kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15.